Why the study?
In patients with structural heart disease and LVEF > 35%, the benefit of VT catheter ablation and the subsequent need for ongoing ICD therapy remain uncertain.
Does cardiomyopathy type (ischaemic vs non-ischaemic) impact the recurrence of ventricular tachycardia after catheter ablation in patients with structural heart disease and LVEF > 35%?
Population
226 consecutive patients with structural heart disease and LVEF > 35% undergoing VT ablation
Comparison
Ischaemic cardiomyopathy vs non-ischaemic cardiomyopathy
Design
Observational cohort study
Authors
Loading...
Higher VT recurrence in NICM may warrant cautious counseling; leaves open optimal ablation strategies for prospective validation.
Does cardiomyopathy type (ischaemic vs non-ischaemic) impact the recurrence of ventricular tachycardia after catheter ablation in patients with structural heart disease and LVEF > 35%?
In patients with structural heart disease and LVEF > 35%, VT ablation yields higher acute success and lower long-term recurrence in ischaemic compared to non-ischaemic cardiomyopathy.
Waezsada et al. (2026) studied this question.